Vascular calcification
AssigneesCambridge Enterprise Limited, King's College London
InventorsMelinda Duer, David Reid, Catherine Shanahan
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of a poly(ADP ribose) polymerase (PARP) inhibitor and/or a tetracycline, for treating, preventing or ameliorating medial vascular calcification, and to pharmaceutical compositions comprising PARP inhibitors or tetracycline.
Claims15
A method of treating, preventing or ameliorating medial vascular calcification or intimal atherosclerotic calcification in a subject, the method comprising administering to a subject in need of such treatment, a therapeutically effective amount of a poly(ADP ribose) polymerase (PARP) inhibitor and/or a tetracycline, or a pharmaceutically acceptable salt or solvate thereof.
A pharmaceutical composition for treating medial vascular calcification or intimal atherosclerotic calcification comprising a PARP inhibitor and/or tetracycline, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable vehicle.
Dependencies are inferred from the claim text.